The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer
Official Title: Randomized Phase II Study of 3 vs 6 Courses of Neoadjuvant Carboplatin-paclitaxel Chemotherapy in Stage IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma
Study ID: NCT02125513
Brief Summary: The purpose of this study is to define whether 6 courses of neoadjuvant chemotherapy can lead to a higher rate of complete cytoreductive surgery compared with 3 courses of neoadjuvant chemotherapy in patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
S.Orsola-Malpighi Hospital, Bologna, , Italy
Azienda Ospedaliero-Universitaria di Parma - Oncologia Medica, Parma, , Italy
IRCCS Ospedale Santa Maria Nuova, Reggio Emilia, , Italy
Fondazione Policlinico Universitario A. Gemelli, Rome, , Italy
Azienda Ospedaliero-Universitaria Santa Maria della Misericordia di Udine, Reparto di Oncologia, Udine, , Italy
Name: Claudio Zamagni, MD
Affiliation: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Role: PRINCIPAL_INVESTIGATOR